Concepedia

Author

Kevin Greenslade

UCB Pharma (United Kingdom)ORCID

Also Known As

K Greenslade, K. Greenslade, Kevin Greenslade, Kevin J. Greenslade

15

Publications

726

Citations

11

H-Index

41

Concepts

All Affiliations

UCB Pharma (United Kingdom)William Harvey Research Institute
KG

About

Kevin Greenslade is an author at UCB Pharma (United Kingdom) specializing in medicine, immunology, and antibody engineering.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

485

2

Natural Sciences

2

2

281

3

Allergy

2

2

126

4

Biochemistry

1

1

46

5

Biomolecular Engineering

1

1

46

Kevin Greenslade

×

11

Publications

722

Citations

11

H-Index

YearCitations

Characterization of the Structural Features and Interactions of Sclerostin

Václav Veverka, Alistair J. Henry, Patrick M. Slocombe,

Journal of Biological Chemistry

2009

235

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

Bryan Smith, Rocío Lledó‐García, Kate L. Dixon,

mAbs

2018

110

Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone

Massimo Marenzana, Kevin Greenslade, Alison Eddleston,

Arthritis & Rheumatism

2011

74

Effects of diacerhein on granuloma induced cartilage breakdown in the mouse

Adrian Moore, Kevin Greenslade, Chandan Alam,

Osteoarthritis and Cartilage

1998

65

Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists

Gill Holdsworth, Kevin Greenslade, Joby K. Jose,

Bone

2017

58

Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions

Omar Qureshi, Tania F. Rowley, Fabian Junker,

Scientific Reports

2017

47

Alternative antibody Fab′ fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering

David P. Humphreys, Sam Heywood, Alistair J. Henry,

Protein Engineering Design and Selection

2007

46

The Effects of Cyclooxygenase 2 Inhibitors on Cartilage Erosion and Bone Loss in a Model of Mycobacterium tuberculosis-Induced Monoarticular Arthritis in the Rat

Derek W. Gilroy, Anneka Tomlinson, Kevin Greenslade,

Inflammation

1998

38

Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis

T. Dreyer, Mittal Shah, Carl Doyle,

Journal of Orthopaedic Translation

2021

20

Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia

Bryan Smith, Louis Christodoulou, Alison Clargo,

International Immunopharmacology

2018

16

Page 1